Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of EC-18 in Preventing the Progression of COVID-19 Infection to Severe Pneumonia or ARDS
Latest Information Update: 05 Apr 2023
At a glance
- Drugs Mosedipimod (Primary)
- Indications COVID-19 pneumonia; Respiratory insufficiency; SARS-CoV-2 acute respiratory disease
- Focus Therapeutic Use
- Sponsors Enzychem Lifesciences Corporation
- 30 Apr 2021 Status changed from not yet recruiting to recruiting.
- 27 Oct 2020 Planned initiation date changed from 6 Oct 2020 to 16 Nov 2020.
- 28 Sep 2020 Status changed from planning to not yet recruiting.